Developer docs
API playgroundTry for free, no card

Search company profiles

CryoHoldco

Full company profile

uuid000e89u

Namestring
CryoHoldco
Websiteurl
cryoholdco.com
Company typeenum
Private
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersJalisco, Mexico
HQ citystring
Jalisco
HQ countrystring
Mexico
HQ regionstring
Latin America
Markets served

Serves global market

Keyword5 values
stem cell banking, cord blood storage, cryopreservation services, biological sample storage, stem cell storage
Industry2 codes
1Cell & Tissue Banking (biobanking, cord blood/tissue)
CodeHLAAAGAEPrimaryYes
2Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low)
CodeHLAGAGAKPrimaryNo
NAICS code1 code
  • Blood and Organ Banks621991
Product category
Stem Cell Banking Services
Social media profiles1 record
Cost components4 values
Infrastructure, Personnel, Operations, Marketing or Sales
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

CryoHoldco is a holding company that operates stem cell and cord blood banking services in Latin America, headquartered in Jalisco, Mexico. Through its subsidiaries it provides cryopreservation and long-term storage of biological samples such as cord blood stem cells for families and individuals in the region. The company participates in the global cord blood banking services market, which is forecast to grow from USD 46.81 billion in 2026 to USD 100.83 billion by 2032.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Stem Cell Banking and Cryopreservation
CategoryStem Cell Banking Services
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Cell Preserve / Banco de Sangre de Cordón Umbilical (LatAm peer)
TypeRegional player
Description

A Latin American stem cell bank serving Brazil and surrounding markets. Regional peer that competes with CryoHoldco across overlapping Spanish/Portuguese-speaking Latin American geographies.

2Cells4Life
TypeDirect peer
Description

UK-based cord blood and tissue bank with multi-market presence. Comparable as a cord blood bank focused on private family storage with proprietary processing technology claims.

3StemCyte
TypeDirect peer
Description

Global cord blood bank operating in the US, India, and other markets with both family and public banking. Directly comparable to CryoHoldco in core cryopreservation service and international expansion strategy.

4Smart Cells International
TypeDirect peer
Description

UK-based private cord blood stem cell bank serving international markets including the Middle East and Asia. Comparable as a focused private stem cell storage operator with international distribution.

5FamilyCord
TypeDirect peer
Description

US-based private cord blood and cord tissue bank. Direct peer in private family banking with similar processing and cryogenic storage service offering.

6Cryo-Cell International
TypeDirect peer
Description

One of the largest and oldest US-based cord blood banks offering family storage and processing services globally. Directly comparable to CryoHoldco as a pure-play private/family cord blood banking operator with international reach.

7New York Blood Center / National Cord Blood Program
TypeBroad incumbent
Description

Operates one of the largest public cord blood banks in the world. Comparable as a major cord blood banking institution with cryopreservation infrastructure, though operating in public rather than private banking.

8ViaCord
TypeDirect peer
Description

A leading cord blood and tissue banking service owned by Revvity. Comparable to CryoHoldco in core service offering (umbilical cord blood collection, processing, and cryogenic storage) for expectant parents.

9Cord Blood Registry (CBR)
TypeDirect peer
Description

The largest US family cord blood bank, now part of California Cryobank Life Sciences. Direct competitor to CryoHoldco in family cord blood banking with the largest US inventory under management.

10CryoSave (now BioStorage Technologies / Salveo)
TypeDirect peer
Description

European-headquartered stem cell bank with operations across multiple countries including emerging markets. Direct peer given geographic diversification strategy and family cord blood storage model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CryoHoldco

Stem Cell Banking Servicescryoholdco.com

CryoHoldco firmographics

Firmographics
Name
CryoHoldco
Website
https://cryoholdco.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

CryoHoldco industry classification

Industry
Product category
Stem Cell Banking Services
NAICS
Blood and Organ Banks (621991)
akta.pro primary industry
Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
akta.pro secondary industry
Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK)

Keywords

  • Stem cell banking
  • Cord blood storage
  • Cryopreservation services
  • Biological sample storage
  • Stem cell storage

Where CryoHoldco is headquartered

Location

Headquarters

HQ city
Jalisco
HQ country
Mexico
HQ region
Latin America

Markets served

CryoHoldco business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Infrastructure, Personnel, Operations, Marketing or Sales

CryoHoldco product offering

Product offering

Core offering

CryoHoldco is a holding company that operates stem cell and cord blood banking services in Latin America, headquartered in Jalisco, Mexico. Through its subsidiaries it provides cryopreservation and long-term storage of biological samples such as cord blood stem cells for families and individuals in the region. The company participates in the global cord blood banking services market, which is forecast to grow from USD 46.81 billion in 2026 to USD 100.83 billion by 2032.

Differentiator

Problem solved

Functional benefit

Products and services

  • Stem Cell Banking and Cryopreservation

Companies that use CryoHoldco

Customer profile

Ideal customer profiles1 record

CryoHoldco technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

CryoHoldco partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves1 record

Expansion highlights2 records

CryoHoldco competitors and assessment

Company assessment

Regional players

Direct peers

  • Cells4Life: UK-based cord blood and tissue bank with multi-market presence. Comparable as a cord blood bank focused on private family storage with proprietary processing technology claims.
  • StemCyte: Global cord blood bank operating in the US, India, and other markets with both family and public banking. Directly comparable to CryoHoldco in core cryopreservation service and international expansion strategy.
  • Smart Cells International: UK-based private cord blood stem cell bank serving international markets including the Middle East and Asia. Comparable as a focused private stem cell storage operator with international distribution.
  • FamilyCord: US-based private cord blood and cord tissue bank. Direct peer in private family banking with similar processing and cryogenic storage service offering.
  • Cryo-Cell International: One of the largest and oldest US-based cord blood banks offering family storage and processing services globally. Directly comparable to CryoHoldco as a pure-play private/family cord blood banking operator with international reach.
  • ViaCord: A leading cord blood and tissue banking service owned by Revvity. Comparable to CryoHoldco in core service offering (umbilical cord blood collection, processing, and cryogenic storage) for expectant parents.
  • Cord Blood Registry (CBR): The largest US family cord blood bank, now part of California Cryobank Life Sciences. Direct competitor to CryoHoldco in family cord blood banking with the largest US inventory under management.
  • CryoSave (now BioStorage Technologies / Salveo): European-headquartered stem cell bank with operations across multiple countries including emerging markets. Direct peer given geographic diversification strategy and family cord blood storage model.

Broad incumbents

  • New York Blood Center / National Cord Blood Program: Operates one of the largest public cord blood banks in the world. Comparable as a major cord blood banking institution with cryopreservation infrastructure, though operating in public rather than private banking.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights3 records

Customer concentration

CryoHoldco social profiles

Digital presence

CryoHoldco financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CryoHoldco leadership team

Management profile

Number of profiles

CryoHoldco funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CryoHoldco M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CryoHoldco

What does CryoHoldco do?

CryoHoldco is a holding company that operates stem cell and cord blood banking services in Latin America, headquartered in Jalisco, Mexico. Through its subsidiaries it provides cryopreservation and long-term storage of biological samples such as cord blood stem cells for families and individuals in the region. The company participates in the global cord blood banking services market, which is forecast to grow from USD 46.81 billion in 2026 to USD 100.83 billion by 2032.

When was CryoHoldco founded?

CryoHoldco was founded in 2015. It employs 251 to 500 people.

Where is CryoHoldco based?

CryoHoldco is headquartered in Jalisco, Mexico, in the Latin America region.

Who are CryoHoldco's main competitors?

Cell Preserve / Banco de Sangre de Cordón Umbilical (LatAm peer) is listed as a regional player. Direct peers are Cells4Life, StemCyte, Smart Cells International, FamilyCord, Cryo-Cell International, ViaCord, Cord Blood Registry (CBR) and CryoSave (now BioStorage Technologies / Salveo). New York Blood Center / National Cord Blood Program is listed as a broad incumbent.

Does CryoHoldco have an API?

No public API is recorded for CryoHoldco.

What industry is CryoHoldco in?

CryoHoldco's product category is Stem Cell Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAGAGAK, Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low). Its NAICS code is 621991.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioinformantPivotal Trends Impacting the Global Cord Blood Industry in 2025This industry report identifies six pivotal trends reshaping the global cord blood and tissue banking sector in 2025: diversification of stem cell storage services, integration with genetic testing and fertility services, ongoing market consolidation, vertical integration into therapeutic development, and advances in cord blood cell expansion technology. Gamida Cell achieved a landmark milestone in April 2023 by securing the first-ever U.S. FDA approval for an expanded cord blood cell therapy (Omisirge), representing a breakthrough in addressing the cell dose limitation that has historically restricted cord blood transplantation in adult patients. Major consolidation activity includes CooperCompanies' $1.6 billion acquisition of Generate Life Sciences in 2021 and Cryoholdco emerging as the dominant player in Latin America with over 275,000 stem cell units, while Sanpower Group controls over 1.2 million units across China and Southeast Asia.PR Newswire2018 Global Cord Blood Banking Industry ReportBioInformant, a Washington-based market research firm specializing in the stem cell industry, has released its 265-page '2018 Global Cord Blood Banking Industry Report,' which provides trend data, market sizing, and five-year projections through 2022 for cord blood and tissue storage on a global basis. The report identifies key industry threats including low utilization rates and high transplantation costs, alongside opportunities such as emerging stem cell storage services, regulatory pathways in major markets, and consolidation through holding companies. The research highlights active acquisition strategies by Cryoholdco in Latin America and Sanpower Group in Asia, as well as technological advances in cord blood expansion being pursued by companies including Gamida Cell, Nohla Therapeutics, Novartis, and Fate Therapeutics.